Dermatosis papulosa nigra (DPN) consists of small, harmless, dark brown to black papules — typically 1 to 5 mm — found predominantly on the cheeks, temples, forehead, and neck of individuals with darker skin. DPN affects up to 35% of Black Americans and is commonly seen in South Asian, East Asian, and Hispanic populations. The lesions begin appearing in adolescence or early adulthood and gradually increase in number with age. They are widely recognizable but are frequently misidentified as moles.
The essential decision: DPN is a benign variant of seborrheic keratosis, driven by FGFR3 mutations and strongly genetic (40–50% family history). Removal is entirely elective and cosmetic. In head-to-head trials in patients with Fitzpatrick IV–VI skin, electrodesiccation and KTP (532 nm) laser produced comparable lesion clearance, but KTP laser caused significantly less discomfort (p = 0.002). Cryotherapy carries unacceptable hypopigmentation risk in dark skin and should generally be avoided. The most important safety step is a test-lesion protocol: treat only a few lesions first, wait 4 to 6 weeks to evaluate for post-inflammatory hyperpigmentation (PIH) or hypopigmentation, and then proceed with broader treatment only if the test patch heals well. Expect $150 to $500 per session, entirely out of pocket — insurance does not cover DPN removal.
What Is Dermatosis Papulosa Nigra, and Why Do People of Color Get It?
Biology and Genetics
DPN is classified as a variant of seborrheic keratosis (SK) — the most common benign skin tumor in adults. Like conventional SK, DPN shares activating mutations in the FGFR3 (fibroblast growth factor receptor 3) gene, which drives the characteristic keratinocyte proliferation. This shared molecular biology is why DPN and SK are histologically similar under the microscope: both show acanthosis, papillomatosis, and hyperkeratosis, though DPN lesions tend to be smaller, flatter, and more deeply pigmented.
The key difference is clinical context: DPN occurs almost exclusively in individuals with Fitzpatrick skin types III–VI, has a strong genetic component, and presents with a distinctive bilateral, symmetric distribution on the face and upper body.
Epidemiology
| Feature | Details |
|---|---|
| Prevalence | Up to 35% of Black Americans; common in South Asian, East Asian, and Hispanic populations |
| Family history | 40–50% of patients report at least one affected parent |
| Sex distribution | More common in women than men |
| Onset | Adolescence or early adulthood (typically mid-teens to 20s) |
| Progression | Lesions increase in number and size with age; existing lesions do not spontaneously regress |
| Location | Malar cheeks, temples, forehead, periorbital area, neck, upper chest, back |
The genetic basis explains why DPN is an inherent feature of certain skin types rather than a disease that can be "cured" — removal treats existing lesions, but new ones continue to develop throughout life.
Clinical Appearance
DPN presents as flat-topped to slightly raised, well-demarcated, hyperpigmented papules ranging from 1 to 5 mm in diameter. They are typically:
- Uniformly dark brown to black
- Smooth or slightly verrucous (rough) surfaced
- Sessile (broad-based) or pedunculated (on a tiny stalk)
- Painless and non-pruritic
- Bilateral and symmetric in distribution
The lesion count varies from a handful to hundreds. Patients frequently describe them as "tiny moles," "black moles," or "black dots" that have been present since their twenties and that their mother, father, or grandmother also has.
Quality-of-Life Impact and Cultural Context
Although DPN is medically benign, its impact on quality of life should not be dismissed. Survey data from dermatology practices treating skin of color patients show that many individuals with DPN report significant cosmetic concern, particularly as lesion counts increase with age. Common patient concerns include:
- Perceived aging: Patients associate increasing numbers of facial papules with aging and seek removal for aesthetic rejuvenation, especially in the periorbital and malar regions.
- Social self-consciousness: Visible facial lesions, particularly in large numbers, may affect social confidence and professional self-presentation.
- Cultural context: In communities of African, Caribbean, and South Asian descent, DPN is so common that it is often considered a normal part of aging rather than a medical condition. Some patients delay seeking evaluation because they do not realize removal is an option — or because they have been told by providers unfamiliar with skin of color that "nothing can be done." Both responses underserve the patient.
- Confusion with concerning lesions: Patients and family members sometimes worry that DPN papules are cancerous, particularly when lesion counts are high or when individual lesions are dark. Accurate diagnosis and reassurance are themselves therapeutic.
The decision to pursue DPN removal should be patient-driven, informed by realistic expectations about recurrence and new lesion development, and performed by a provider experienced with pigmentary safety in Fitzpatrick IV–VI skin.
How Is DPN Different from a Skin Tag, a Mole, or Melanoma?
Accurate identification is essential before any cosmetic removal. The periocular and malar face hosts several lesions that patients and some providers confuse with DPN.
| Feature | DPN | Skin Tag (Acrochordon) | Melanocytic Nevus (Mole) | Seborrheic Keratosis | Melanoma |
|---|---|---|---|---|---|
| Appearance | Flat-topped, 1–5 mm, dark, smooth | Soft, pedunculated, skin-colored to brown, 1–5 mm | Round/oval, uniform color, flat or raised, 2–6 mm | "Stuck-on," waxy, variable color, 3–20 mm | Asymmetric, irregular border, color variation, growing |
| Surface | Smooth or slightly rough | Smooth, soft, compressible | Smooth, uniform | Rough, verrucous, greasy | Irregular, may ulcerate |
| Distribution | Bilateral malar, temples, forehead, neck | Neck, axillae, groin folds | Anywhere | Sun-exposed and trunk | Anywhere; often on legs (women) or back (men) |
| Pigment | Uniformly dark in Fitz III–VI | Usually skin-colored to light brown | Uniform tan to dark brown | Variable (flesh to dark brown) | Mixed colors (black, brown, red, white, blue) |
| Dermoscopy | Cerebriform pattern, comedo-like openings | Homogeneous, no pigment network | Globular or reticular pattern | Milia-like cysts, comedo-like openings | Atypical network, irregular dots, blue-white veil |
| Concern | Cosmetic | Cosmetic; irritation from friction | Usually benign; atypical nevi need monitoring | Benign | Urgent biopsy required |
Red flags requiring biopsy before cosmetic removal:
- Any lesion that is growing rapidly, changing color, bleeding, or ulcerating
- Asymmetric or irregularly bordered pigmented lesion
- Solitary dark papule that differs from the patient's other lesions
- Lesion with mixed colors (especially if blue, black, red, and white are present)
- Any lesion the patient or provider is uncertain about
DPN lesions are characteristically uniform, multiple, bilateral, symmetric, stable, and consistent with the patient's family history. A single atypical lesion amid dozens of typical DPN should be biopsied to rule out melanoma before treating the field.
Which DPN Removal Method Is Safest for Avoiding Dark or Light Spots in Brown and Black Skin?
This is the central question for DPN patients, because the population most affected by DPN — Fitzpatrick types IV–VI — is also the population most susceptible to post-inflammatory pigmentary complications from any destructive treatment. The available evidence from randomized and comparative trials provides useful, if imperfect, guidance.
Electrodesiccation (Electrocautery)
Electrodesiccation uses low-power, high-frequency electrical current through a fine-tip probe to desiccate and destroy the papule. It is the most widely available and studied method for DPN.
Trial evidence:
- Kundu et al. (2009) — Randomized split-face trial in 14 patients with Fitzpatrick IV–VI skin: electrodesiccation and KTP (532 nm) laser produced comparable efficacy (combined-rater p = 0.50).
- Garcia et al. (2010) — Comparison of electrodesiccation, pulsed dye laser (PDL), and curettage in 10 patients: no significant difference in clearance, cosmetic outcome, or PIH among the three modalities.
- JDD systematic review — Across 15 studies, electrodesiccation achieved a pooled clearance rate of 92.5%, compared to 88% for laser modalities. The difference was not statistically significant.
- South African low-intensity electrodesiccation study — Confirmed that low-power settings in skin of color produce good clearance with manageable PIH when treatment is kept superficial.
Advantages: Widely available, inexpensive, effective, no capital-intensive laser equipment required. Disadvantages: Operator-dependent; excessive power or contact duration increases PIH/hypo risk. Less comfortable than KTP laser.
KTP Laser (532 nm)
The potassium-titanyl-phosphate (KTP) laser targets melanin and hemoglobin at 532 nm, selectively heating and destroying the pigmented papule with less non-specific thermal damage than electrodesiccation.
Trial evidence:
- Kundu et al. (2009): Comparable efficacy to electrodesiccation (p = 0.50) but significantly less discomfort (p = 0.002). This is the strongest head-to-head evidence available.
Advantages: Less painful than electrodesiccation; selective melanin targeting may limit collateral thermal injury. Disadvantages: Higher cost per session; not available at all practices; 532 nm wavelength absorbs strongly in melanin-rich skin, creating a narrow therapeutic window between lesion destruction and epidermal damage in Fitzpatrick V–VI.
CO2 Laser (10,600 nm)
The CO2 laser vaporizes tissue non-selectively, ablating the papule layer by layer.
Trial evidence:
- A 2016 study (cited in StatPearls) treated 45 patients with CO2 laser. Patient satisfaction was high after an average of 3 sessions, but 28% of patients had recurrence of a few lesions after ablation.
Advantages: Effective ablation; hemostatic. Disadvantages: Higher PIH and scarring risk in dark skin than electrodesiccation or KTP; the 28% recurrence rate is notable; multiple sessions needed.
Pulsed Dye Laser (PDL, 595 nm)
PDL targets hemoglobin but also destroys pigmented superficial lesions through photothermal damage.
Trial evidence:
- Garcia et al. (2010): Comparable clearance and cosmetic outcome to electrodesiccation and curettage, but most painful of the three modalities tested.
Advantages: Selective targeting; widely available in dermatology offices. Disadvantages: Higher pain than electrodesiccation; cost similar to other laser options; limited additional benefit over electrodesiccation for DPN specifically.
Curettage (Curette Scraping)
A small curette is used to shave the papule off the skin surface.
Trial evidence:
- Garcia et al. (2010): Comparable to electrodesiccation and PDL for clearance and cosmetic outcome.
Advantages: Quick, simple, no equipment beyond a dermal curette. Disadvantages: Risk of hypo- or hyperpigmentation if too deep; no hemostasis (minor bleeding); less precise than laser for very small lesions.
Cryotherapy (Liquid Nitrogen)
Liquid nitrogen freezes and destroys the papule through ice-crystal formation.
Evidence and risk:
- StatPearls specifically warns that cryotherapy risks hypopigmentation from melanocyte damage and should be used with extreme caution in skin of color.
- Melanocytes are highly sensitive to cold injury. The uncontrolled freeze depth damages melanocytes beyond the lesion boundary, producing white spots (leukoderma) that may be permanent — a cosmetically devastating outcome for the same patients seeking cosmetic improvement.
Recommendation: Cryotherapy is generally not recommended for DPN in Fitzpatrick IV–VI skin. If used, it should be applied with minimal freeze time and only after the patient understands the hypopigmentation risk.
Modality Comparison Summary
| Method | Clearance | Recurrence | Discomfort | PIH risk (Fitz IV–VI) | Hypopigmentation risk | Cost/session (US) | Evidence level |
|---|---|---|---|---|---|---|---|
| Electrodesiccation | 92.5% (systematic review) | Moderate | Moderate | Moderate (low if conservative) | Low | $150–$400 | RCT + systematic review |
| KTP laser (532 nm) | Comparable to ED | Moderate | Low (p=0.002 vs ED) | Moderate | Low–moderate | $300–$600 | RCT (Kundu 2009) |
| CO2 laser (10,600 nm) | High | 28% after avg 3 sessions | Moderate | Moderate–high | Low | $400–$800 | Case series |
| PDL (595 nm) | Comparable to ED | Moderate | High (most painful) | Moderate | Low | $300–$600 | Comparative trial |
| Curettage | Comparable to ED | Moderate | Moderate | Moderate | Moderate | $150–$400 | Comparative trial |
| Cryotherapy | Moderate | High | Moderate | Low | HIGH | $100–$250 | Contraindicated in dark skin |
The Test-Lesion Protocol: Treating DPN Safely in Skin of Color
The single most important safety practice for DPN removal in Fitzpatrick IV–VI skin is a test-lesion protocol before full-field treatment. This approach is recommended by StatPearls and endorsed across the skin-of-color dermatology literature.
Step-by-Step Protocol
Initial consultation and diagnosis confirmation. A board-certified dermatologist examines the lesions, confirms DPN (vs. melanoma, skin tags, or atypical nevi), and assesses Fitzpatrick skin type and pigmentary history.
Test treatment of 3 to 5 lesions. The provider treats a small number of representative lesions using the chosen modality (usually electrodesiccation or KTP laser) at conservative settings.
Wait 4 to 6 weeks. The treated test lesions are allowed to heal completely. During this period, the patient and provider assess:
- Did the lesions clear adequately?
- Is there PIH (darkening) at the treatment sites?
- Is there hypopigmentation (lightening) at the treatment sites?
- Is the cosmetic result acceptable to the patient?
Adjust and proceed (or stop). If the test patch heals without pigmentary complication, the provider treats the remaining lesions in staged sessions (typically 10 to 30 lesions per visit). If PIH or hypopigmentation occurs, the treatment plan is modified (lower settings, different modality, pre-treatment with tyrosinase inhibitors) or abandoned.
Pre- and Post-Treatment Pigment Management
- Pre-treatment (2–4 weeks before): Topical hydroquinone 4%, azelaic acid 15–20%, or tranexamic acid to suppress melanocyte hyperactivity and reduce PIH risk.
- Post-treatment: Strict broad-spectrum SPF 30+ sunscreen, reapplied every 2 hours during healing. Continued tyrosinase inhibitor for 4 to 8 weeks. Avoid heat exposure, friction, and picking.
- If PIH develops: Topical hydroquinone, azelaic acid, retinoid, or combination product (e.g., modified Kligman formula) for 8 to 12 weeks. PIH from superficial treatments typically resolves, but may take months.
Will DPN Come Back After Removal, and Will New Ones Keep Appearing?
Understanding the natural history of DPN is essential for setting realistic expectations:
Recurrence of Treated Lesions
Complete destruction of a DPN papule (the entire keratinocyte proliferation) eliminates that specific lesion. However:
- The CO2 laser literature reports 28% recurrence after an average of 3 sessions (2016 study via StatPearls), likely from residual basal keratinocytes regrowing.
- Electrodesiccation and KTP laser likely have similar rates, though the published data is less specific.
- Incomplete destruction (undertreating to avoid PIH) increases the chance of regrowth from the base.
New Lesion Development
DPN is a genetically determined condition. Treating existing lesions does not prevent new ones from forming. Patients should expect:
- New papules to continue appearing throughout adulthood, especially in sun-exposed areas.
- The rate of new lesion development to be similar to their pre-treatment rate.
- Periodic maintenance or touch-up sessions (every 1 to 2 years) to address new growths.
The Honest Conversation
The responsible counseling message — which many clinic marketing pages omit — is that DPN removal is ongoing cosmetic maintenance, not a permanent fix. Patients who understand this have higher satisfaction than those who expect a one-time cure. A dermatologist who promises "permanent removal" of all DPN without acknowledging new lesion development is over-promising.
What Does DPN Removal Cost, and Does Insurance Cover It?
Insurance Status
DPN is classified as a benign, asymptomatic cosmetic condition. Health insurance does not cover removal. The only exception is if a biopsy is required to rule out melanoma — the biopsy procedure itself may be covered, but the cosmetic removal of the remaining DPN lesions is not.
Cost by Method
| Method | Approximate cost per session (US) | Notes |
|---|---|---|
| Electrodesiccation | $150–$400 | Lower end; widely available |
| KTP laser | $300–$600 | Higher cost; less available |
| CO2 laser | $400–$800 | Highest laser cost; most aggressive |
| PDL | $300–$600 | Comparable to KTP |
| Curettage | $150–$400 | Comparable to electrodesiccation |
| Cryotherapy | $100–$250 | Not recommended for dark skin |
Total treatment cost depends on the number of lesions and sessions required. A typical patient with 20 to 50 facial DPN lesions treated over 2 to 4 sessions might spend $300 to $2,400 for the initial clearance course, with periodic touch-up costs thereafter.
Some practices offer per-lesion pricing ($10–$30 per lesion) rather than per-session pricing. For patients with many lesions, per-session pricing is usually more economical.
Should You See a Dermatologist or Can a Med Spa Remove DPN?
A board-certified dermatologist — ideally one experienced with skin of color — is the appropriate provider for DPN evaluation and removal for several reasons:
- Diagnostic accuracy: DPN must be distinguished from melanoma, atypical nevi, and other pigmented lesions. A dermatologist is trained to recognize the differential and can biopsy if needed.
- Skin-of-color expertise: The test-lesion protocol, conservative treatment settings, and pigment-management strategy require experience with Fitzpatrick IV–VI skin response patterns.
- Biopsy capability: If any lesion looks atypical, a shave biopsy can be performed immediately.
- Equipment: KTP and PDL lasers are more commonly found in dermatology offices than in general med spas.
Med spas without physician supervision and dermatologic expertise may not recognize atypical lesions, may over-treat, and may not have protocols for managing PIH in dark skin. For acne scar treatment in skin of color and PIH after aesthetic procedures and other pigment-sensitive conditions, the same principle applies: expertise with the specific patient population matters more than the device brand.
Frequently Asked Questions
Can I remove DPN at home with apple cider vinegar or tea tree oil?
No. Home remedies do not have evidence supporting DPN removal and carry significant risk of chemical burns, infection, PIH, and scarring — particularly on facial skin. DPN papules are keratinized growths that require physical destruction (electrodesiccation, laser, curettage) for clearance. Social media recommendations for vinegar, castor oil, black salve, or bloodroot are dangerous and should be avoided.
Is DPN a sign of cancer or something dangerous?
No. DPN is a benign keratinocytic proliferation — a variant of seborrheic keratosis. It does not transform into melanoma or any other cancer. However, melanoma can occasionally mimic a DPN papule, which is why any atypical, changing, bleeding, or solitary lesion that differs from the patient's other papules should be biopsied. The presence of DPN itself is not a cancer risk factor.
Will electrodesiccation or laser leave a scar on dark skin?
Scarring is uncommon when treatment is performed by an experienced provider at conservative settings. The more common concern is post-inflammatory hyperpigmentation (temporary darkening) or, less commonly, hypopigmentation (lightening), both of which are pigmentary changes rather than textural scars. The test-lesion protocol — treating a few lesions first and waiting to see how they heal — is the best way to assess your individual scarring and pigmentation risk before committing to full-field treatment.
Should I see a dermatologist or can a med spa remove DPN?
A board-certified dermatologist is strongly recommended, especially one with skin-of-color experience. DPN requires accurate diagnosis (ruling out melanoma), a skin-type-appropriate treatment plan, the test-lesion protocol, and pigment management expertise. Med spas without dermatologic supervision may lack the diagnostic training and skin-of-color protocols needed for safe DPN removal.
Sources
- StatPearls — Dermatosis Papulosa Nigra (Xiao A, Muse ME, Ettefagh L). NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK534205
- Kundu RV, Joshi SS, Suh KY, et al. — Comparison of electrodesiccation and potassium-titanyl-phosphate laser for treatment of dermatosis papulosa nigra. Dermatol Surg 2009;35(7):1079–1083. https://pubmed.ncbi.nlm.nih.gov/19469798
- Garcia MS, Azari R, Eisen DB — Treatment of dermatosis papulosa nigra in 10 patients: a comparison trial of electrodesiccation, pulsed dye laser, and curettage. Dermatol Surg 2010;36(12):1968–1972. https://pubmed.ncbi.nlm.nih.gov/21040130
- DermNet — Dermatosis Papulosa Nigra. https://dermnetnz.org/topics/dermatosis-papulosa-nigra
- JDD (Journal of Drugs in Dermatology) — A Systematic Review on the Treatment of Dermatosis Papulosa Nigra. https://jddonline.com/articles/a-systematic-review-on-the-treatment-of-dermatosis-papulosa-nigra-S1545961621P0467X
